Low-Dose Testosterone for Teen Girls: What You Need to Know Before Turning 18

Why a Teen Girl Might Be Prescribed Low-Dose Testosterone

Testosterone in adolescent girls is not a common prescription. When it appears on a teen girl's medication list, there is usually a specific verified diagnosis behind it. The most common scenarios are primary or secondary hypogonadism caused by Turner syndrome, hypopituitarism, premature ovarian insufficiency (POI), or adrenal insufficiency where androgen output is measurably absent or critically low.

Turner syndrome, affecting roughly 1 in 2,000 female births, causes gonadal dysgenesis that leaves many girls with near-zero ovarian androgen production alongside estrogen deficiency. Standard management focuses on estrogen replacement first, but some specialists add a micro-dose androgen component to support bone density, lean mass, energy, and in some cases libido as the teen moves into mid-to-late adolescence.

Hypopituitarism from a craniopharyngioma resection or other pituitary injury can eliminate both ovarian and adrenal androgen signaling simultaneously. In these situations, replacing only estrogen and progesterone may leave measurable androgen deficiency unaddressed.

What Low-Dose Actually Means in This Population

"Low-dose" for an adolescent girl typically means compounded transdermal preparations delivering 0.5 to 2 mg of testosterone per day, titrated to keep total serum testosterone in the low-normal physiologic female range of roughly 15 to 50 ng/dL. This is orders of magnitude below male replacement doses of 50 to 100 mg daily. The goal is not masculinization. The goal is restoring a physiologic floor that the ovaries and adrenal glands are failing to produce on their own.

Conditions That Do Not Justify Testosterone in Teens

Testosterone is not indicated in adolescent girls for fatigue without a confirmed hormonal deficiency, for low mood where estrogen and thyroid status have not been assessed first, or for athletic performance. Off-label androgen prescribing in teens without documented deficiency carries real risks including early epiphyseal closure and irreversible virilization at higher doses.

Sex-Specific Physiology: Why the Adolescent Female Body Responds Differently

The adolescent female hormonal environment is dominated by rising estradiol from the maturing ovarian follicle pool. Testosterone in this context does not behave the way it does in a post-menopausal woman or a man. Several physiologic differences matter clinically.

Aromatization Rate Is Higher in Adolescence

Adipose tissue and the developing ovary both aromatize testosterone to estradiol at high rates during puberty. A dose that produces a safe serum testosterone level in a 35-year-old woman may convert to more estradiol than intended in a 14-year-old with active ovarian tissue. This is one reason pediatric endocrinologists use compounded preparations with granular dose control rather than commercial products designed for adult women.

Bone Age and Epiphyseal Plates

Androgens accelerate bone maturation. In a growing girl who still has open growth plates, supraphysiologic testosterone can close epiphyses prematurely and compromise final adult height. Bone age X-rays are recommended every 6 to 12 months in adolescents receiving any androgen therapy to confirm growth plates remain appropriately open for chronologic age.

The Menstrual Cycle Complicates Interpretation

In a girl who has begun menstruating, serum testosterone fluctuates across the cycle. Levels peak near ovulation at values roughly 20 to 30 percent above the early follicular baseline, according to data from the Study of Women's Health Across the Nation (SWAN). Blood draws for therapeutic drug monitoring should be standardized to the early follicular phase (days 2 to 5) to avoid misinterpreting a natural mid-cycle rise as a dosing problem.

Androgen Sensitivity Varies by SHBG

Sex hormone-binding globulin (SHBG) is high during active estrogen-dominant puberty. High SHBG binds more testosterone, reducing free (biologically active) testosterone. A girl on oral contraceptives for cycle regulation has even higher SHBG, meaning the same total testosterone dose will produce a lower free testosterone level. Free or calculated free testosterone alongside total testosterone gives a more complete picture of androgen availability in any teen on combined hormonal contraception.

Conditions in Teen Girls Where Testosterone Intersects

PCOS: Too Much, Not Too Little

Polycystic ovary syndrome (PCOS) is the most common androgen-related condition in adolescent girls, affecting 6 to 13 percent of this age group. In PCOS, testosterone is already elevated, not deficient. A teen with PCOS is not a candidate for testosterone therapy. She may need anti-androgen treatment instead. Prescribers and patients should be clear: PCOS is the condition where excess testosterone causes symptoms, while the scenarios described in this article involve deficiency.

Premature Ovarian Insufficiency

POI before age 40, and certainly before 18, is rare but real. ACOG Practice Bulletin No. 234 addresses POI management and prioritizes estrogen-progestin replacement. Testosterone as an adjunct in adolescent POI is not standard of care but may be considered by a specialist in documented symptomatic androgen deficiency alongside estrogen therapy.

Congenital Adrenal Hyperplasia (CAH)

Girls with CAH have disrupted androgen synthesis. Depending on the enzyme defect and steroid replacement regimen, some girls with CAH are under-androgenized while receiving supraphysiologic glucocorticoids. Androgen management in CAH is complex and should remain in the hands of a pediatric endocrinologist through the teen years.

Turner Syndrome and Bone Health

Girls with Turner syndrome have significantly elevated fracture risk due to absent gonadal hormone production. Estrogen replacement is the primary tool, but some longitudinal data suggest that adequate androgen levels may contribute to periosteal bone apposition in ways estrogen alone does not fully replicate. A 2019 review in the European Journal of Endocrinology highlighted ongoing uncertainty about optimal androgen management in Turner syndrome, underscoring the evidence gap in this population.

Pregnancy, Lactation, and Contraception: Required Reading

This section is non-negotiable. If you are a teen girl prescribed low-dose testosterone, or a parent or clinician reading for a teen patient, this information must be understood before the prescription is filled.

Testosterone is a known teratogen. Exposure of a female fetus to exogenous androgens during the first trimester causes virilization of external genitalia, a harm that cannot be undone after birth. The FDA has issued explicit warnings about testosterone use in women who are or may become pregnant.

What This Means for a Sexually Active Teen

Any adolescent girl who is sexually active and prescribed testosterone must use reliable contraception. The options with the lowest failure rate in typical use are:

• Intrauterine devices (hormonal or copper), with failure rates below 1 percent per year
• Subdermal implant (etonogestrel), also below 1 percent per year
• Combined or progestin-only pills, with perfect-use failure around 0.3 percent but typical-use failure of 7 to 9 percent per year

The copper IUD is the only hormonal-free option that does not affect SHBG (relevant for testosterone monitoring accuracy, as discussed above).

Pregnancy Category and Human Data

Testosterone is classified as FDA Pregnancy Category X. There is no safe dose in pregnancy. If a teen on testosterone suspects pregnancy, she should stop the medication immediately and contact her prescriber the same day. A urine pregnancy test should be part of routine monitoring for any sexually active teen on this therapy.

Lactation

Testosterone transfer into breast milk has not been studied in formal lactation pharmacokinetic trials. Based on the known lipophilicity of testosterone and its low molecular weight, transfer is expected. The medication should not be used during breastfeeding. This matters less at the 12 to 17 age range but is relevant in the 16 to 17 age group and as teens move into early adulthood.

Skin Transfer Risk

Compounded testosterone gels and creams transfer to others through skin contact. A teen applying testosterone to her arm must wash her hands immediately and cover the application site. This matters for infant siblings and for sexual partners who may be pregnant or trying to conceive.

Monitoring While on Low-Dose Testosterone (Adolescent Protocol)

Monitoring in adolescent girls is more intensive than in adults because the developing body is more sensitive to androgen effects. The following schedule reflects general specialist practice rather than a single published guideline, given the evidence gap in this population.

Proposed Adolescent Monitoring Framework (WomanRx Clinical Editorial)

| Timepoint | Test | Purpose | |-----------|------|---------| | Baseline | Total and free testosterone, SHBG, LH, FSH, estradiol, lipid panel, bone age X-ray | Confirm deficiency, document growth plate status | | 6-8 weeks after dose change | Total testosterone (early follicular if menstruating) | Confirm target range; avoid mid-cycle draws | | Every 3-6 months | Total testosterone, SHBG, hematocrit, lipid panel | Safety monitoring | | Every 6-12 months | Bone age X-ray (if growth plates open) | Protect final adult height | | Annually | Bone density (DXA) if primary hypogonadism | Fracture risk baseline | | Each visit | Blood pressure, acne assessment, clitoral size, voice change check | Virilization screen |

Signs of over-replacement that require dose reduction: acne worsening beyond baseline, clitoral enlargement, voice deepening, or serum testosterone above 70 ng/dL on two consecutive draws.

Who This Therapy Is Right For, and Who It Is Not

Right For: Life-Stage Criteria

Low-dose testosterone in the 12 to 17 age range is appropriate when all of the following are true:

• A named diagnosis explains androgen deficiency (Turner syndrome, hypopituitarism, adrenal insufficiency, or POI confirmed by two FSH draws above 25 IU/L at least one month apart)
• Estrogen and progesterone replacement is already optimized or not applicable
• A pediatric endocrinologist or reproductive endocrinologist is supervising prescribing
• Contraception has been discussed explicitly if the teen is or may become sexually active
• Bone age monitoring is in place

Not Right For: Conditions That Do Not Qualify

• PCOS with elevated androgens
• Fatigue or low mood without a documented hormonal deficiency
• Athletic performance or muscle building
• Gender-affirming care, which follows entirely different protocols and dosing targets outside the scope of this article

The Role of a Specialist

General pediatricians and family medicine providers are rarely positioned to manage this therapy alone. A pediatric endocrinologist or, as the teen approaches 17 to 18, a reproductive endocrinologist or adult endocrinologist with women's-health expertise should be directing the prescription.

Transition to Adult Care: The 16-to-21 Window

The shift from pediatric to adult endocrinology or reproductive endocrinology is the most clinically fragile period for a teen on testosterone therapy. Gaps in this handoff are common and carry real risk: doses go un-reviewed, monitoring lapses, and teens who are now legally adults may end up self-managing a teratogenic medication without supervision.

When to Start Planning

Transition planning should begin no later than age 16. This is consistent with the American Academy of Pediatrics and the American College of Physicians joint consensus statement on transition care, which recommends initiating structured transition processes by mid-adolescence rather than waiting for the 18th birthday.

What the Handoff Should Include

A complete transition packet from the pediatric team to the adult provider should document:

1. The specific diagnosis that justified testosterone prescribing
2. Every dose used and the rationale for the current dose
3. All prior monitoring labs with dates and results
4. Bone age films and any DXA results
5. Contraception status and the name of the contraceptive method in use
6. Any side effects or dose adjustments made and why
7. The teen's understanding of why she takes this medication

The 18-to-21 Gap Is Real

Research published in the Journal of Adolescent Health found that young adults with chronic conditions who experienced a gap in care around age 18 had significantly worse health outcomes than those with a structured transition. For a teen on testosterone, a care gap can mean: no prescriber to renew the compounded medication, no monitoring of testosterone levels, and no reinforcement of contraception use at the very age when sexual activity becomes more common.

Adult providers receiving a new 18-year-old patient on compounded testosterone should not assume the previous dose was calibrated for an adult body. Growth plate closure, changes in SHBG due to stopping oral contraceptives, and the shift from pediatric to adult normative ranges all require a fresh clinical assessment.

Choosing an Adult Provider

The adult provider taking over care should be comfortable with:

• Compounded hormone prescribing and pharmacy coordination
• Female androgen physiology, not male testosterone replacement
• The specific underlying diagnosis (Turner syndrome managed by a general internist is often under-served)
• Contraception counseling as part of every visit

Reproductive endocrinologists, menopause-certified practitioners (NAMS), and women's-health NPs with endocrine training are often better positioned than general endocrinologists who primarily manage male hypogonadism.

What Adolescent Girls and Their Families Should Ask at Every Appointment

Direct questions produce better care. Before and after the transition to adult care, these are the questions worth asking out loud:

• "What is my current total testosterone level, and is it in the target range for a female my age?"
• "Are my growth plates fully closed, and do I still need bone age monitoring?"
• "Does my contraceptive method interact with my testosterone dose or my testosterone monitoring?"
• "What signs of over-replacement should I watch for between visits?"
• "Who will be prescribing and monitoring my testosterone after I turn 18, and have they received my full medical history?"
• "If I want to try to get pregnant in the future, how do I stop testosterone safely and what happens to my fertility?"

The last question opens a longer conversation. In girls with Turner syndrome or POI, natural conception is usually not possible and fertility options (oocyte donation, embryo adoption) need to be discussed early. In girls with hypopituitarism, fertility may be achievable with gonadotropin induction, but testosterone must be discontinued before any fertility attempt.

Evidence Gaps: What We Do Not Yet Know

WomanRx reviewer Dr. Elena Vasquez, MD, notes: "There are no published randomized controlled trials of low-dose testosterone specifically in adolescent girls with hypogonadism. Every recommendation in this space is extrapolated from adult women's data, case series, or expert consensus. Families and teens deserve to hear that directly, not have it buried in fine print."

Women have been systematically under-represented in hormone trials, and adolescent girls are even further from the center of the research base. The specific questions that remain unanswered include:

• What is the optimal target range for total and free testosterone in girls aged 12 to 17 compared to adult women?
• Does low-dose androgen supplementation in Turner syndrome improve bone density outcomes beyond estrogen alone, and if so, at what dose?
• How does compounded testosterone bioavailability differ across adolescent skin versus adult skin?
• What are the long-term virilization risks of micro-dose transdermal testosterone over 5 to 10 years of adolescent use?

Honest acknowledgment of these gaps is not a reason to avoid treatment where it is clearly indicated. It is a reason to keep doses at the minimum necessary, monitor consistently, and revisit the indication at every transition point.